化合物 LDN-214117|T1944|TargetMol

LDN-214117
1627503-67-6

￥297 2mg 起订

￥497 5mg 起订

￥913 10mg 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 LDN-214117

英文名称：: LDN-214117

CAS号：: 1627503-67-6

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.85%

产品类别：: 抑制剂

货号：: T1944

Product Introduction

Bioactivity

名称	LDN-214117
描述	LDN-214117 is a potent and selective ALK2 inhibitor.
细胞实验	Cells are seeded at 25000 cells per well in 96-well plates and incubated for 2 h at 37℃ and 5% CO2. Compounds of LDN-214117 or DMSO are diluted in DMEM and added at ?nal compound concentrations of 1, 10, and 100 μM. Cells are incubated for 4 and 24 h, after which the media is discarded. Cells are lysed by adding 30 μL of passive lysis bu?er and shaken at RT for 15 min. Cell viability is determined by quantifying the ATP present in each well by adding 10 μL of Cell Titer Glo per well and measuring the light output by Spectramax L luminometer. Data is normalized to 100% viability for cells receiving only DMSO.(Only for Reference)
激酶实验	ALK2 kinase assay: Puri?ed recombinant ALK2 proteins, ATP, ATP[γ-32P], and dephosphorylated casein at ?nal concentrations of 2.5 nM, 6 μM, 0.05 μCi/μL , and 0.5 mg/mL, respectively, are aliquoted in kinase bu?er containing 0.2% BSA supplemented with 10 mM MnCl2 into 96-microwell plates, in combination with inhibitor compounds diluted at varying concentrations (0.01 nM to 100 μM). Positive control samples lacking inhibitor compounds, and negative controls lacking recombinant kinase, are also measured. The mixture is reacted at RT for 45 min, quenched with a ?nal concentration of 2% phosphoric acid. The reaction mixture is transferred to 96-well P81 phosphocellulose ?lter plates and bound for 5 min. The plates are washed 20 times with 150 μL of 1% phosphoric acid solution per well by vacuum manifold. Plates are dried at RT for 1 h, sealed, and assayed with Microscint 20 scintillation ?uid using a Spectramax L luminometer. Data is normalized to positive controls at 100% enzyme activity, with negative controls being subtracted as background.
体内活性	LDN-214117对BMP6比对BMP2或BMP4表现出相对的选择性抑制。在基于细胞的测定中,LDN-214117对BMP6表现出选择性抑制,IC50约为100 nM,作用于BMP6比作用于TGF-β1选择性高164倍。LDN-214117高度抑制的激酶为ALK2,IC50为24 nM,其次为TNIK,RIPK2和ABL1。LDN-214117选择性抑制ALK2和ALK1激酶活性,抑制作用高于ALK3激酶。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	Ethanol : 42 mg/mL (100 mM) DMSO : 4.2 mg/mL (10 mM), Sonication is recommended.
关键字	ALK2 \| BMP4 \| BMP2 \| Transforming growth factor beta receptors \| LDN-214117 \| BMP6 \| TGF-β Receptor \| diffuse intrinsic pontine glioma(DIPG) \| oral \| ALK3 \| fibrodysplasia ossificans progressiva (FOP) \| ALK5 \| type I receptor kinases \| ALK1 \| LDN214117 \| bone morphogenetic proteins (BMPs) \| LDN 214117
相关产品	Monocrotaline \| Pirfenidone \| Ceritinib \| A 83-01 \| Chromenone 1 \| LY-364947 \| BMP signaling agonist sb4 \| Alectinib hydrochloride \| SB-431542 \| Galunisertib \| Alantolactone \| Hydrochlorothiazide
相关库	抑制剂库 \| 血管生成库 \| 经典已知活性库 \| 已知活性化合物库 \| 激酶抑制剂库 \| 干细胞分化化合物库 \| 抗肥胖化合物库 \| TGF-β/Smad靶点化合物库 \| 膜蛋白靶向化合物库 \| 酪氨酸激酶分子库

LDN-214117|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务